TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Pharvaris ( (PHVS) ) has provided an announcement.
On December 3, 2025, Pharvaris announced positive topline data from its RAPIDe-3 pivotal study, highlighting the potential of deucrictibant for on-demand treatment of HAE attacks. The study demonstrated that deucrictibant met its primary and all secondary endpoints, showing faster symptom relief and a well-tolerated safety profile compared to placebo. These results are expected to support marketing authorization applications in 2026, potentially positioning deucrictibant as a significant treatment option for HAE, offering both on-demand and prophylactic control of angioedema attacks.
The most recent analyst rating on (PHVS) stock is a Buy with a $37.00 price target. To see the full list of analyst forecasts on Pharvaris stock, see the PHVS Stock Forecast page.
Spark’s Take on PHVS Stock
According to Spark, TipRanks’ AI Analyst, PHVS is a Neutral.
Pharvaris exhibits significant financial difficulties, with no revenue and ongoing losses, resulting in a low financial performance score. Despite some technical momentum, the valuation is poor due to negative earnings. The stock’s overall score is affected by these financial and valuation challenges, despite its technical strength.
To see Spark’s full report on PHVS stock, click here.
More about Pharvaris
Pharvaris is a late-stage biopharmaceutical company focused on developing novel, oral bradykinin B2 receptor antagonists to address unmet needs in bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH).
Average Trading Volume: 254,275
Technical Sentiment Signal: Buy
Current Market Cap: $1.67B
Find detailed analytics on PHVS stock on TipRanks’ Stock Analysis page.